Last reviewed · How we verify
A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions
This study was open-label, randomized, fed, single-dose, 2-groups, 2 periods, crossover designe to compare the safety and pharmacokinetics of UI068 and co-administration of UIC202205 and UIC202206.
Details
| Lead sponsor | Korea United Pharm. Inc. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 35 |
| Start date | Sat Mar 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- administration of UI068
- administration of UIC202205, UIC202206
Countries
South Korea